Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: The BIOCRT study

Truong, Quynh A.; Januzzi, James L.; Szymonifka, Jackie; Thai, Wai-ee; Wai, Bryan; Lavender, Zachary; Sharma, Umesh C; Sandoval, Ryan; Grunau, Zachary; Basnet, Sandeep; Babatunde, Adefolakemi; Ajijola, Olujimi A.; Min, James K.; Singh, Jagmeet P.

doi:10.1016/j.hrthm.2014.07.007

Cited by 51 publications

(44 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is significant potential to develop and incorporate single and multimarker strategies to better risk stratify and treat patients with arrhythmias and resynchronization. Our recent work [131] on multimarker strategies has begun influencing our practice, but much of it still needs validation in prospective randomized studies.…”

Section: Discussionmentioning

confidence: 99%

Biomarkers in electrophysiology: role in arrhythmias and resynchronization therapy

Bose

Truong

Singh

2015

J Interv Card Electrophysiol

Self Cite

View full text Add to dashboard Cite

Circulating biomarkers related to inflammation, neurohormones, myocardial stress, and necrosis have been associated with commonly encountered arrhythmic disorders such as atrial fibrillation (AF) and more malignant processes including ventricular arrhythmias (VA) and sudden cardiac death (SCD). Both direct and indirect biomarkers implicated in the heart failure cascade have potential prognostic value in patients undergoing cardiac resynchronization therapy (CRT). This review will focus on the role of biomarkers in AF, history of SCD, and CRT with an emphasis to improve clinical risk assessment for arrhythmias and patient selection for device therapy. Notably, information obtained from biomarkers may supplement traditional diagnostic and imaging techniques, thus providing an additional benefit in the management of patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Biomarkers in electrophysiology: role in arrhythmias and resynchronization therapy

Bose

Truong

Singh

2015

J Interv Card Electrophysiol

Self Cite

View full text Add to dashboard Cite

show abstract

“…For a long time, the source of circulating sST2 in cardiac disease was presumed to be myocardial following in vitro data showing load induction of ST2 mRNA in neonatal rat cardiac myocytes [48]. More recent work, however, suggests that in human cardiac disease, the vascular endothelial cells might be the predominant source of sST2, rather than the human myocardium [93,94,157].…”

Section: Biology Of Sst2mentioning

confidence: 99%

Soluble ST2 in heart failure

Dieplinger

Mueller

2015

Clinica Chimica Acta

124

View full text Add to dashboard Cite

“…Therefore, in this part of the study, we tried to understand the role of serum Gal-3 in AF patients after establishing its effects in cellular and animal models. A recent clinical trial suggested that coronary sinus sampling of HF biomarkers, such as Gal-3, may be more appropriate than peripheral venous blood levels for predicting the outcome of cardiac resynchronization therapy [15]. Thus, we compared the levels of coronary sinus serum Gal-3 in patients who underwent pure mitral valve cardiac surgery.…”

Section: Discussionmentioning

confidence: 99%

Activation of TGF-β1/α-SMA/Col I Profibrotic Pathway in Fibroblasts by Galectin-3 Contributes to Atrial Fibrosis in Experimental Models and Patients

Shen

Wang

Min

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: This study aimed to evaluate whether galectin-3 (Gal-3) contributes actively to atrial fibrosis both in patients and experimental atrial fibrillation (AF) models. Methods: Mouse HL-1 cardiomyocytes were subjected to rapid electrical stimulation (RES) to explore Gal-3 expression and secretion levels by western blotting (WB) and enzyme linked immunosorbent assay (ELISA). Neonatal rat cardiac fibroblasts were treated with conditioned culture medium and recombinant human Gal-3 to evaluate the activation of the transforming growth factor (TGF)-β1/α-smooth muscle actin (SMA)/collagen I (Col I) profibrotic pathway (WB) and fibroblast proliferation with a Cell Counting Kit-8 (CCK-8). Furthermore, in the rapid atrial pacing (RAP) rabbit AF model, atrial Gal-3 expression and its effects on the profibrotic pathway were evaluated (WB and Masson’s trichrome staining). Moreover, 44 consecutive patients who underwent single mitral valve repair/replacement were included, consisting of 28 patients with persistent AF (PeAF) and 16 with sinus rhythm (SR). Coronary sinus blood was also sampled to test circulating Gal-3 levels (ELISA), and atrial myocardium Gal-3 and its downstream TGF-β1/α-SMA pathway were also measured by WB and immunohistochemical staining. Results: Gal-3 expression in HL-1 cells and its secretion level in culture medium were greatly increased after 24 h RES. Treatment of neonatal rat cardiac fibroblasts with conditioned media collected from the RES group or recombinant human Gal-3 protein (10 and 30 µg/mL) for 72 h induced the activation of the TGF-β1/α-SMA/Col I profibrotic pathway. RAP increased Gal-3 levels and activated the TGF-β1/α-SMA/Col I pathway in rabbit left atria, while the Gal-3 inhibitor N-acetyllactosamine, injected at 4.5 mg/kg every 3 days, mitigated these adverse changes. Furthermore, Gal-3 levels in coronary sinus blood samples and myocardial Gal-3 expression levels were higher in the PeAF patients than in the SR patients, and higher level profibrotic pathway activation was also confirmed. Conclusions: Activation of Gal-3 expression in the atria can subsequently activate the TGF-β1/α-SMA/Col I pathway in cardiac fibroblasts, which may enhance atrial fibrosis.

show abstract

Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: The BIOCRT study

Abstract: Background-A significant minority of patients receiving cardiac resynchronization therapy (CRT) remain non-responsive to this intervention.

Cited by 51 publications

References 32 publications

Biomarkers in electrophysiology: role in arrhythmias and resynchronization therapy

Biomarkers in electrophysiology: role in arrhythmias and resynchronization therapy

Soluble ST2 in heart failure

Activation of TGF-β1/α-SMA/Col I Profibrotic Pathway in Fibroblasts by Galectin-3 Contributes to Atrial Fibrosis in Experimental Models and Patients

Contact Info

Product

Resources

About